**Supplementary Table 1: Comparison with published IIM cohorts from different ethnicities**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Characteristics | Our cohort | Porkodi et.al.,(2002)9 | Xio Ming Shu et.al., (2011)2 | Euromyositis registry (2017)27 | KJ chinniah et.al.,(2020)28 |
| n | 175 | 87 | 188 | 3067 | 104 |
| Median(IQR) age at onset | 38(27.5,48.5) | 25-35 | 43.8(15.8) | 49 (16) | 36.8(14.7) |
| Gender ratio( M:F) | 1:3.3 | 1:2.3 | 1:2.1 | 1:2.2 | 1:4.8 |
| Ethnicity | India | India | China | Caucasian | African and Indian |
| Median(IQR) disease duration at presentation (months) | 4(1,7) | NA | NA | 8(3,22) | 42(16,103) |
| Median(IQR) duration of follow up (months) | 26.5(6,72) | NA | 90 | 36 (18,72) | 33.5(13,100.8) |
| DM/PM/OM/ASS | 78/25/45/11 | 28/24/30 | 53/21/14.4/0 | 31/27/12/17 | 25/25/40 |
| Juvenile onset | 8.6 | 5 | 3.7 | 3 | 5.8 |
| **Calcinosis(%)**OverallJDM | 7.420 |  | 4.7 | 644 |  |
| Cancer (%) | 4 | 1.1 | 5.9 | 13 | 4.8 |
| MMT-8 | 61(49-69) |  - |  - | NA |  - |
| Dysphagia (%) | 29.1 | 33.3 | 39.9 | 39 | 43.4 |
| Dysphonia (%) | 8 | 4.6 | 11 | NA | 19.2 |
| Respiratory muscle weakness(%) | 3.4 | 9.2 |  - |  - |  - |
| ILD (%) | 13.7 | 9.2 | 48.9 | 30 | 27 |
| Cardiac (%) | 6.3 | 5.7 | 34 | 9 | 14.4 |
| ANA (%)n=157 | 56 | 67.3 | NA | NA | 70.4 |
| Jo-1/Non Jo-1/Mi-2/SRP (N=119) | 11.7/6.7/5/2.5 | NA | NA | NA | Done in a subset |
| Ro52/U1RNP/Pm-Scl/Ku (N= 137) | 37.1/30.5/5.7/4.9 | NA | NA | NA | Done in asubset<50% |
| **Treatment (%)**MethotrexateAzathioprineMycophenolateCyclophosphamideIV IgRituximabMedian no. of immunosuppressants | 5229.718.96.82.810.8 1(1,2) | 57.242.812.46021.4 |  | 715123191272(1-3) | 5037.77.710.619.23.8 |
| **Course (%)**Monocyclic/polycyclic/chronious continuous | 11.7/39.3/48.9 |  | 15.1/79.5/5.4 |  |  |
| MDI >0Median | 58.71(1,2) |  | 71.8 |  |  |
| **HAQ (%)**=0>0Median | 63.736.20(0,0.2) |  | 83.316.7 | 0.75(0.131.5) |  |
| Death (%) | 13.7 | 11.5 | 17 | NA | 7.7 |

DM- Dermatomycosis, PM - polymyositis, OM - overlap myositis, ASS- antisynthetase syndrome, JM- Juvenile Myositis, ILD- Interstitial Lung Disease, MMT8- Manual Muscle Testing, MITAX- myositis intention to treat activity index, HAQ-Health Assessment questionnaire; MDI- Myositis Damage Index; MRS-Muscle Ranking Score

**Supplementary Table 2 : Complications**

|  |
| --- |
| **Complication (n)** |
| LRIPyelonephritisCellulitisAbscessTBFungal ballZoster | 7221613 | CADDMHTNOsteoporosisAVNCataractThrombosis - venousChronic liver diseaseGI bleed | 445224321 |